National Research Tomsk Polytechnic University, Liu Yongsheng, Xu Tianqi, Vorobjeva A. G. Anzhelika Grigorjevna, Loftenius Annika, Bodenko V. V. Vitalina Vasiljevna, . . . Tolmachev V. M. Vladimir Maksimilianovich. (2023). Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab; Cancers; Vol. 15 - iss. 9. 2023. https://doi.org/10.3390/cancers15092409
Citação do estilo Chicago (17ª ed.)National Research Tomsk Polytechnic University, Liu Yongsheng, Xu Tianqi, Vorobjeva A. G. Anzhelika Grigorjevna, Loftenius Annika, Bodenko V. V. Vitalina Vasiljevna, Orlova A. M. Anna Markovna, Frejd Y. F. Fredrik, e Tolmachev V. M. Vladimir Maksimilianovich. Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab; Cancers; Vol. 15 - Iss. 9. 2023, 2023. https://doi.org/10.3390/cancers15092409.
Citação MLA (9ª ed.)National Research Tomsk Polytechnic University, et al. Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab; Cancers; Vol. 15 - Iss. 9. 2023, 2023. https://doi.org/10.3390/cancers15092409.